Next Article in Journal
Is Personalized Mechanical Thrombectomy Based on Clot Characteristics Feasible? A Radiomics Model Using NCECT to Predict FPE in AIS Patients Undergoing Thromboaspiration
Previous Article in Journal
Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Erectile Dysfunction in Diabetic Patients
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 14
Issue 12
10.3390/jcm14124020
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Prospective Assessment of Cardiac Iron Deposition, Morphology, and Function by Magnetic Resonance Imaging in Non-Transfusion-Dependent and Neo-Transfusion-Dependent Thalassemia

by
Antonella Meloni
1,*,
Laura Pistoia
2,
Filomena Longo
3,
Anna Spasiano
4,
Valerio Cecinati
5,
Elisabetta Corigliano
6,
Zelia Borsellino
7,
Ilaria Fotzi
8,
Vincenzo Positano
1,
Michela Zerbini
9,
Stefania Renne
10,
Luigi Barbuto
11,
Alberto Clemente
12 and
Paolo Ricchi
4
1
Bioengineering Unit, Fondazione G. Monasterio CNR-Regione Toscana, 56124 Pisa, Italy
2
Unità Operativa Complessa Ricerca Clinica, Fondazione G. Monasterio CNR-Regione Toscana, 56124 Pisa, Italy
3
Dipartimento di Medicina Specialistica—Day Hospital della Talassemia e delle Emoglobinopatie, Azienda Ospedaliero-Universitaria Arcispedale “S. Anna”, 44124 Cona, FE, Italy
4
Unità Operativa Semplice Dipartimentale Malattie Rare del Globulo Rosso, Azienda Ospedaliera di Rilievo Nazionale “A. Cardarelli”, 80131 Napoli, Italy
5
Struttura Semplice di Microcitemia, Ospedale “SS. Annunziata” ASL Taranto, 74123 Taranto, Italy
6
Ematologia Microcitemia, Ospedale San Giovanni di Dio—ASP Crotone, 88900 Crotone, Italy
7
Unità Operativa Complessa Ematologia con Talassemia, ARNAS Civico “Benfratelli-Di Cristina”, 90134 Palermo, Italy
8
SOC Oncologia, Ematologia e Trapianto di Cellule Staminali Emopoietiche, Meyer Children’s Hospital IRCCS, 50139 Firenze, Italy
9
Diagnostica per Immagini e Radiologia Interventistica, Ospedale del Delta, 44023 Lagosanto, FE, Italy
10
Struttura Complessa di Cardioradiologia-UTIC, Presidio Ospedaliero “Giovanni Paolo II”, 88046 Lamezia Terme, CZ, Italy
11
Unità Operativa Complessa Radiologia Generale e di Pronto Soccorso, Azienda Ospedaliera di Rilievo Nazionale “A. Cardarelli”, 80131 Napoli, Italy
12
Department of Radiology, Fondazione G. Monasterio CNR-Regione Toscana, 56124 Pisa, Italy
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2025, 14(12), 4020; https://doi.org/10.3390/jcm14124020
Submission received: 9 May 2025 / Revised: 30 May 2025 / Accepted: 4 June 2025 / Published: 6 June 2025
(This article belongs to the Section Hematology)
Versions Notes

Abstract

:
Objectives: We compared changes in hepatic and cardiac iron levels, left ventricular (LV) and right ventricular (RV) dimensions and function, and bi-atrial areas, all assessed through magnetic resonance imaging (MRI), between patients with non-transfusion-dependent thalassemia (NTDT) and those with neo-transfusion-dependent thalassemia (neo-TDT) over an 18-month follow-up period. Methods: We included 32 NTDT patients (42.78 ± 12.62 years, 53.1% females) and 58 neo-TDT (>4 transfusions per year) patients (44.08 ± 14.13 years, 46.6% females), consecutively enrolled in the Extension-Myocardial Iron Overload in Thalassemia project. Iron overload was quantified by T2* technique, biventricular function and atrial areas by cine images. Macroscopic myocardial fibrosis was detected by the late gadolinium enhancement technique. Results: Changes in cardiac and hepatic iron levels, in biventricular ejection fractions, in LV mass index, and bi-atrial areas were comparable between the two groups. A trend of worsening biventricular dimensions was observed in the NTDT group, while the neo-TDT group showed an improvement (decrease) in biventricular size (LV stroke volume index: p = 0.036; LV cardiac index: p = 0.031; RV end-diastolic volume index: p = 0.034; RV stroke volume index: p = 0.033). The inter-group comparison showed significant differences in the changes of biventricular end-diastolic volume indexes (LV: p = 0.011 and RV: p = 0.034) and stroke volume indexes (LV: p = 0.036 and RV: p = 0.033) and in the cardiac index (p < 0.0001). At both MRI scans, the frequency of replacement myocardial fibrosis was comparable between the two groups. Conclusions: Our 18-month longitudinal data revealed distinct patterns of cardiac remodeling in NTDT and neo-TDT patients. The progressive ventricular dilation observed in NTDT patients highlights the need for careful MRI monitoring and potential interventions to address the long-term cardiac consequences of anemia.

1. Introduction

Thalassemia is a group of inherited hemoglobinopathies characterized by mutations in the genes responsible for producing the globin chains of hemoglobin, leading to ineffective erythropoiesis, hemolysis, and chronic anemia [1,2]. Non-transfusion-dependent thalassemia (NTDT) refers to the subset of thalassemia patients who do not require regular, lifelong blood transfusions [3,4]. This disease group encompasses a range of clinically diverse thalassemia forms, including beta-thalassemia intermedia (β-TI), hemoglobin E/β-thalassemia, and α-thalassemia intermedia [5]. NTDT patients typically experience mild anemia, and they may require occasional transfusion support during specific clinical situations, such as infection, pregnancy, or episodes of growth failure [4,5,6]. Over time, however, a significant proportion of NTDT patients may develop a need for regular blood transfusions as the disease progresses. Although not without risks [7,8,9,10], these transfusions are crucial in managing or preventing complications such as thrombosis, extramedullary hematopoiesis, pulmonary hypertension, leg ulcers, and cholelithiasis, and, in addition, they help reduce excessive gastrointestinal iron absorption [11,12,13,14,15,16,17]. The subset of NTDT patients requiring frequent transfusions is referred to as neo-transfusion-dependent thalassemia (neo-TDT) to distinguish them from individuals with long-standing transfusion-dependent thalassemia (TDT) [18].
Cardiac involvement is a significant component of the clinical picture of both NTDT and neo-TDT patients [17,19,20], though it has been relatively underexplored in the neo-TDT group. Cardiac magnetic resonance (CMR) is a powerful, non-invasive imaging technique that offers comprehensive assessments of both structural and functional cardiac abnormalities [21,22,23]. CMR’s high accuracy and reproducibility make it the gold standard for evaluating systolic function and cardiac chamber size [24]. Additionally, CMR can assess myocardial tissue composition, detecting changes such as edema or fibrosis [25,26], and it is uniquely capable of quantifying myocardial iron overload using the T2* technique [27,28].
Conversely to hepatic iron overload, myocardial iron overload has not been recognized as a significant clinical issue in NTDT patients [29,30,31,32,33,34]. Similarly, neo-TDT patients exhibit a low cardiac iron burden, likely due to the protective effect of residual expanded erythropoiesis, which may help prevent myocardial iron overload linked with transfusional iron accumulation [14,35,36].
However, recent CMR studies have shown that cardiac iron levels are higher in neo-TDT patients compared to NTDT patients [33,37]. On the other side, the same studies demonstrated a reduced ventricular dilation among neo-TDT patients, suggesting that blood transfusions may have a protective effect in mitigating the hemodynamic consequences of chronic anemia. The heart’s response to prolonged anemia involves compensatory mechanisms such as increased stroke volume and reduced peripheral vascular resistance, which result in ventricular dilation to accommodate the increased circulatory demands [38,39,40,41]. While these adaptations may initially maintain cardiac output, they place long-term stress on the heart, potentially leading to heart failure and other complications if not adequately managed.
The baseline comparisons of cardiac findings provide the foundation for assessing longitudinal trends in cardiac iron levels and function in a real-world clinical setting. This multicenter study aimed to compare the changes in cardiac iron deposition, size, and function between NTDT and neo-TDT patients over a follow-up of 18 months.

2. Materials and Methods

2.1. Study Population

The E-MIOT (Extension-Myocardial Iron Overload in Thalassemia) project is a nationwide network in Italy, consisting of 66 thalassemia centers and 15 MRI sites, where magnetic resonance imaging (MRI) image acquisition and analysis are carried out using a homogeneous, standardized, and validated approach [42]. All centers are connected through a web-based database that collects all clinical, instrumental, and laboratory data of the patients.
Eligibility for inclusion in the E-MIOT project was determined by the following criteria: (1) male and female subjects of any age diagnosed with thalassemia syndromes or structural hemoglobinopathies requiring MRI for the quantification of tissue iron overload; (2) provision of duly signed informed consent; (3) written consent authorizing the use and disclosure of protected health information; and (4) no absolute contraindications preventing the performance of the MRI examination.
We retrospectively included all 90 β-TI patients (43.62 ± 13.55 years, 44 females) consecutively enrolled in the E-MIOT project who performed an MRI follow-up study at 18 ± 3 months, according to the protocol. This schedule represents a compromise between the recommended monitoring intervals based on baseline cardiac iron levels [28] and the practical availability of MRI services in Italy.
Patients were categorized into two groups based on the transfusion regimen. The NTDT group was constituted by 32 (35.6%) patients. Of them, 13 patients were transfusion naïve, and 19 had received sporadic blood transfusions. The neo-TDT group included 58 (64.4%) patients who followed a regular transfusion regimen (>I4 transfusions per year), started at a mean age of 23.12 ± 19.83 years.
The study was conducted in accordance with the Declaration of Helsinki and received approval from the ethical committees of all MRI centers participating in the E-MIOT project. Informed consent was signed by all patients.

2.2. MRI

MRI exams were performed on clinical 1.5 T scanners (GE Healthcare, Milwaukee, WI, USA; Philips, Best, The Netherlands; Siemens Healthineers, Erlangen, Germany) equipped with phased-array coils. Breath-holding in end-expiration and ECG-gating were used.
The T2* technique was used for iron overload assessment. A mid-hepatic slice [43] and three parallel short-axis views (basal, medium, and apical) of the left ventricle (LV) [44] were obtained using gradient–echo multiecho sequences. Image analysis was performed by trained MRI operators (>10 years of experience) using a custom-written, previously validated software (HIPPOMIOT®, Version 2.0, Consiglio Nazionale delle Ricerche and Fondazione Toscana Gabriele Monasterio, Pisa, Italy, Year 2015). Liver T2* values were measured in a circular region of interest, traced in a homogeneous area of parenchyma, avoiding blood vessels [43], and were converted into liver iron concentration (LIC) values employing the most appropriate calibration curve (Wood’s calibration curve) [45]. The software provided the T2* value for the 16 segments of the LV, according to the American Heart Association (AHA)/American College of Cardiology (ACC) standardized myocardial segmentation [46]. An appropriate correction map was used to reduce distortions in segmental T2* values caused by magnetic susceptibility effects [47]. The global heart T2* value was calculated as the mean of the segmental measurements. A LIC exceeding 3 mg/g dry weight was indicative of hepatic iron overload [48]. The value of 20 ms was used as a “conservative” normal value for all 16 segments and the global T2* value [28,49].
For the standard assessment of biventricular function parameters, steady-state free precession (SSFP) cine images were obtained in consecutive short-axis slices encompassing the ventricles and three long-axis slices (two, three, and four chamber views) [50,51]. SSFP images were analyzed in a standard way using commercially available clinical workstations, either MASS software (Medis, Leiden, The Netherlands) or cmr42 (Circle Cardiovascular Imaging Inc., Calgary, Alberta, Canada) [52]. In brief, the endocardial and epicardial borders were manually delineated by an experienced observer on consecutive short-axis cine images at end-diastole and end-systole. End-diastolic volume and end-systolic volume were calculated using Simpson’s rule, without any geometric assumptions. Ejection fraction was determined by dividing the stroke volume (difference between end-diastolic volume and end-systolic volume) by the end-diastolic volume. The left ventricular mass was derived by multiplying muscle volume by its density (1.05 g/cm3). The papillary muscles were delineated and included in the myocardial mass, and the interventricular septum was considered part of the LV. Left and right atrial areas were quantified from the four-chamber view at ventricular end-systole. Biventricular volumes, LV mass, and bi-atrial areas were indexed to the body surface area (BSA), derived using the variation of the Dubois and Dubois formula [53].
For the detection of focal or replacement myocardial fibrosis, late gadolinium enhancement (LGE) images in both short- and long-axis views were acquired 8–18 min following intravenous administration of standard dose (0.2 mmol/kg) of Gadobutrol (Gadovist®; Bayer; Berlin, Germany) using a fast gradient-echo inversion recovery sequence [54]. In case of patient refusal or the presence of renal failure (glomerular filtration rate < 30 mL/min/1.73 m2), LGE images were not acquired. LGE images were visually evaluated to identify the presence and location of LGE. To exclude artifacts, LGE was considered present only if detected in two orthogonal views.

2.3. Biochemical Analysis

Biochemical tests were conducted at the local laboratories of the participating thalassemia centers using standardized, commercially available assay kits. For each participant, the average hemoglobin and serum ferritin levels from the 12 months prior to the CMR scan were determined and included in the analysis.

2.4. Statistical Analysis

Data analysis was performed by using SPSS version 27.0 (IBM Corp, Armonk, NY, USA) statistical package.
The normality of the distribution of the parameters was evaluated using the Kolmogorov-Smirnov test or the Shapiro-Wilk test for a sample size ≤ 50.
Means and standard deviations (SD) were used to describe continuous variables, whereas frequencies and percentages were reported for categorical variables.
The inter-group comparison for the continuous variables at baseline and the changes from baseline (differences between values at follow-up and baseline MRI scans) was carried out using the independent-samples t-test in the case of normal distribution or the Wilcoxon rank-sum test for non-normally distributed data. The comparison between categorical variables was made with the chi-square or Fisher’s exact test, as appropriate.
Analysis of covariance (ANCOVA) was employed to adjust for variables that differed significantly between the two groups at baseline and were significantly related to the dependent variable. A covariate was included if the variable showed both a significant difference between groups and a significant association with the outcome under evaluation. When necessary, outcome variables were log-transformed to achieve normality of residuals and homogeneity of variance.
The association between continuous variables was assessed using Pearson’s test or Spearman’s test, as appropriate based on data distribution.
Depending on the distribution of the variables of interest (normal or not), a paired Student t-test or Wilcoxon signed-rank test was performed to detect significant differences between baseline and follow-up values.
Two-tailed p-values were used for all analyses, and a threshold of p < 0.05 was considered statistically significant.

3. Results

3.1. Comparison of Baseline Data

The clinically and instrumentally relevant baseline findings in the two groups (NTDT vs. neo-TDT) are summarized in Table 1.
Age and sex were comparable between the two groups, while neo-TDT patients were more frequently splenectomized (p = 0.008) and more often receiving chelation therapy (p < 0.0001). Among patients who had undergone splenectomy, those in the neo-TDT group had a significantly younger age at the time of splenectomy compared to those in the NTDT group (17.05 ± 11.79 years vs. 24.20 ± 9.47 years, p = 0.026).
Neo-TDT patients showed significantly higher serum hemoglobin levels (p = 0.003), but no difference between the two groups was detected in serum ferritin levels.
Significantly lower hepatic iron levels were present in the neo-TDT group (p = 0.002), while cardiac iron levels were comparable between the two groups.
Biventricular volumes and LV mass index tended to be lower in neo-TDT patients compared to NTDT patients, but the difference was significant only for the LV end-diastolic volume index (p = 0.034). The neo-TDT group had a significantly lower cardiac index (p = 0.040), while no difference was observed in biventricular ejection fractions. Bi-atrial areas were comparable between the two groups.
The contrast medium was administered in 50.0% of NDT patients and 32.8% of neo-TDT patients (p = 0.108). The frequency of replacement myocardial fibrosis was comparable between the two groups. The septum was involved in all cases, and all patients had a non-ischemic LGE pattern (subendocardial or junctional).

3.2. MRI Changes for NTDT Patients

At the follow-up, no significant changes in mean hemoglobin levels (mean difference: −0.11 ± 0.53 g/dL, p = 0.408) and in mean serum ferritin levels (mean difference: −74.17 ± 395.83 ng/mL, p = 0.400) were found.
The difference in MRI parameters between the two MRI scans for NTDT patients is shown in Table 2.
No significant changes in MRI LIC values and global heart T2* values were detected. Out of the 24 patients with hepatic iron overload at the baseline, only 4 (16.7%) showed a normal MRI LIC at the follow-up MRI. The 50% of patients with a baseline MRI LIC < 3 mg/g dw became pathological at the follow-up MRI. The patient with significant myocardial iron overload (global heart T2* < 20 ms) at baseline showed a normal global heart T2* at the follow-up. At the baseline MRI, this patient was not chelated, but she started the chelation therapy (deferasirox) after that. All the 31 patients without significant myocardial iron overload at the baseline remained free of significant cardiac iron also at the follow-up MRI.
Biventricular volumes, LV mass index, and cardiac index increased at the follow-up, but the changes were not significant. Biventricular ejection fractions and bi-atrial areas remained almost unchanged.
There was no correlation between baseline serum hemoglobin levels and changes in LV function parameters, RV function parameters, or bi-atrial areas (Table 3).
At the follow-up, there were no new occurrences of replacement myocardial fibrosis.

3.3. MRI Changes for Neo-TDT Patients

At the follow-up, no significant changes in mean hemoglobin levels (mean difference: 0.07 ± 0.25 g/dL, p = 0.078) and in mean serum ferritin levels (mean difference: −21.37 ± 371.39 ng/mL, p = 0.837) were found.
The difference in MRI parameters between the two MRI scans for neo-TDT patients is shown in Table 4.
No significant changes in MRI LIC values and global heart T2* values were detected. Out of the 21 patients with hepatic iron overload at the baseline, 7 (33.3%) showed a normal MRI LIC at the follow-up MRI. Among the 37 patients without baseline hepatic iron overload, 9 (24.3%) showed hepatic iron overload at the follow-up. At both the MRI scans, all patients showed a normal global heart T2* value.
At the follow-up, a significant decrease in LV stroke volume index and cardiac index (p = 0.036 and p = 0.031, respectively) and RV end-diastolic volume index and stroke volume index was detected (p = 0.034 and p = 0.033, respectively). Biventricular ejection fractions, LV mass index, and bi-atrial areas were comparable between the two scans.
There was no correlation between baseline serum hemoglobin levels and changes in LV function parameters, RV function parameters, or bi-atrial areas (Table 3).
At the follow-up, there were no new occurrences of replacement myocardial fibrosis.

3.4. Inter-Group Comparison

The comparison of mean changes from baseline in MRI parameters between NTDT and neo-TDT patients is shown in Table 5.
The changes in MRI LIC and global heart T2* values were not significantly different between the two groups.
After adjustment for the baseline LV end-diastolic volume index, there was a statistically significant difference in the change in LV end-diastolic volume index between the two groups (p = 0.011). The changes in biventricular stroke volume indexes and the RV end-diastolic volume index were significantly different between the two groups (LV stroke volume index: p = 0.006, RV stroke volume index: p = 0.018, and RV end-diastolic volume index: p = 0.005), with all these parameters increased in the NTDT group and decreased in the neo-TDT group. The difference in the mean change in cardiac index (positive value for the NTDT group and negative value for the neo-TDT group, p = 0.009) remained significant also after the correction for the baseline value (p < 0.0001). The changes in biventricular end-systolic volume indexes, LV mass index, biventricular ejection fractions, and bi-atrial areas were comparable between the two groups.

4. Discussion

We longitudinally studied hepatic and cardiac siderosis and cardiac size and function in NTDT and neo-TDT patients.
In both patient groups, mean hepatic and cardiac iron levels were similar between the two MRI scans. Nevertheless, the comparison of the frequency of hepatic iron overload revealed important findings. Compared to the neo-TDT group, the NTDT group had a significantly higher prevalence of hepatic IO at the baseline and was characterized by a lower proportion of patients with hepatic IO at the baseline and a normal LIC at the follow-up MRI (16.7% vs. 33.3%) and a higher proportion of patients who developed hepatic IO at the follow-up (50.0% vs. 24.3%). The increased hepatic iron burden in NTDT patients can be attributed to the reduced frequency of iron chelation therapy.
The apparent discrepancy with previous studies, which reported increased cardiac iron levels in the neo-TDT group [33,37] may be attributed to the small sample size of this study. Furthermore, both patient groups maintained low cardiac iron levels, making it difficult to detect significant differences between them. Notably, in the single patient who presented with baseline cardiac iron overload, the initiation of chelation therapy was effective in reducing the cardiac T2* to a normal level, confirming the potential for treatment to manage and reverse cardiac iron overload [55,56,57,58,59].
At baseline, patients with NTDT showed more pronounced ventricular dilation compared to those with neo-TDT, suggesting, in line with previous studies [33,37], that the absence of regular transfusions may exacerbate the ventricular enlargement. The small sample size limited the statistical significance of most clinical parameters related to LV and RV remodeling. The follow-up MRI scans revealed a trend for worsening (increase) in biventricular dimensions for the NTDT group, which could be indicative of progressive cardiac dilation over time due to chronic anemia. In contrast, the neo-TDT group exhibited improvements in all cardiac size parameters, which reflected enhanced cardiac efficiency and better hemodynamic compensation. The decrease was significant for the biventricular stroke volume indexes, the cardiac index, and the RV end-diastolic volume index. The inter-group comparison showed significant differences in the changes of biventricular end-diastolic volume indexes and stroke volume indexes, and the cardiac index. Overall, our findings suggest that regular blood transfusions effectively reduce the negative hemodynamic effects of anemia, improving both short-term cardiac remodeling and providing lasting benefits in the heart’s structural adaptation over time.
Interestingly, we observed no significant differences in baseline values or the changes in biventricular ejection fractions between the two groups. The decline in myocardial systolic function is likely a gradual process, potentially requiring prolonged periods of high cardiac output to manifest. On the other side, a recent study conducted in patients with iron deficiency anemia showed that LV dysfunction can occur early in the progression of myocardial damage, even when the LV ejection fraction remains within normal limits [60]. Indeed, while the LV ejection fraction is the most commonly used index of LV systolic function in clinical practice, it has known limitations [61,62] and it often remains preserved until myocardial dysfunction reaches a more advanced stage, failing to detect early or subclinical dysfunction [63,64,65,66].
In our study, the mean serum hemoglobin at baseline was not correlated with baseline values or changes in biventricular volumes, likely because it does not fully reflect the long-term severity of anemia. Additionally, in the neo-TDT group, the well-controlled pre-transfusion hemoglobin levels make it challenging to identify a correlation, due to high intra-subject variability and the fact that MRI scans were taken at different points during the transfusion cycle. Although cardiac function generally remains stable before and after transfusions, ventricular volumes tend to decrease shortly after a blood transfusion [67]. However, the correction of anemia status in neo-TDT patients is not clearly indicated by the pre-transfusion hemoglobin level alone, as it depends on the post-transfusion hemoglobin level achieved and the transfusion interval. Moreover, the mean hemoglobin level reached is difficult to extrapolate.

Limitations

This study has several limitations that should be acknowledged.
The main limitation of our study is the small sample size, which limits the statistical power and hampers drawing definitive conclusions or making broader inferences about the observed trends.
Another important factor to consider is the individual variability in transfusion regimens and iron chelation therapy, which may affect cardiac outcomes differently in neo-TDT patients. Nnon-“real-life” studies with standardized treatment protocols could help refine our understanding of these effects. Larger studies would allow for more robust statistical analyses, enhance the reliability of the results, and provide a clearer understanding. Additionally, long-term follow-up studies are needed to determine whether the effects of transfusion therapy on cardiac size and function in neo-TDT patients persist over time, as well as to further evaluate potential late-onset complications in patients with NTDT.
Myocardial strain is recognized as a more sensitive marker of myocardial dysfunction than ejection fraction [68]. Strain quantification can be performed using dedicated CMR feature-tracking software applied to routine cine images; however, these tools are not uniformly available across all MRI centers within the E-MIOT Network.

5. Conclusions

Our study highlights the distinct patterns of cardiac remodeling observed in NTDT and neo-TDT patients. NTDT patients show more pronounced increases in ventricular volumes and cardiac index, reflecting the natural progression of the disease in the absence of the beneficial effects of transfusion therapy on cardiac remodeling. Our findings underscore the importance of careful monitoring using MRI and the potential need for interventions in NTDT patients to mitigate the long-term cardiac consequences of anemia. Additionally, this study provides a basis for exploring the impact of emerging hemoglobin-boosting treatments, such as luspatercept and mitapivat, on cardiac size and function parameters in NTDT patients.

Author Contributions

Conceptualization, A.M. and P.R.; methodology, A.M.; software, V.P.; formal analysis, A.M.; investigation, A.M.; resources, F.L., A.S., V.C., E.C., Z.B., I.F., M.Z., S.R., L.B., A.C. and P.R.; data curation, L.P.; writing—original draft preparation, A.M.; writing—review and editing, L.P., F.L., A.S., V.C., E.C., Z.B., I.F., V.P., M.Z., S.R., L.B., A.C. and P.R.; supervision, P.R. and A.C. All authors have read and agreed to the published version of the manuscript.

Funding

The E-MIOT project receives “no-profit support” from industrial sponsorships (Chiesi Farmaceutici S.p.A. and Bayer). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Ethics Committee of Area Vasta Nord Ovest (protocol code 56664, date of approval 8 October 2015).

Informed Consent Statement

Informed consent was obtained from all patients involved in the study.

Data Availability Statement

Data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy concerns.

Acknowledgments

We would like to thank all the colleagues involved in the E-MIOT project (https://emiot.ftgm.it/). We thank all patients for their cooperation. This project is carried out within the framework of the European Reference Network on Rare Haematological Diseases (ERN-EuroBloodNet)-Project ID No 101085717. ERN-EuroBloodNet is partly co-funded by the European Union within the framework of the Fourth EU Health Programme.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Weatherall, D.J.; Clegg, J.B. The Thalassemia Syndromes; Blackwell Science: Oxford, UK, 2001. [Google Scholar]
  2. Sadiq, I.Z.; Abubakar, F.S.; Usman, H.S.; Abdullahi, A.D.; Ibrahim, B.; Kastayal, B.S.; Ibrahim, M.; Hassan, H.A. Thalassemia: Pathophysiology, Diagnosis, and Advances in Treatment. Thalass. Rep. 2024, 14, 81–102. [Google Scholar] [CrossRef]
  3. Weatherall, D.J. The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Rev. 2012, 26 (Suppl. S1), S3–S6. [Google Scholar] [CrossRef] [PubMed]
  4. Musallam, K.M.; Rivella, S.; Vichinsky, E.; Rachmilewitz, E.A. Non-transfusion-dependent thalassemias. Haematologica 2013, 98, 833–844. [Google Scholar] [CrossRef] [PubMed]
  5. Taher, A.; Musallam, K.; Cappellini, M.D. Guidelines for the Management of Non-Transfusion-Dependent β-Thalassaemia [Internet], 3rd ed.; Thalassaemia International Federation: Nicosia, Cyprus, 2023. [Google Scholar]
  6. El-Beshlawy, A.; Dewedar, H.; Hindawi, S.; Alkindi, S.; Tantawy, A.A.; Yassin, M.A.; Taher, A.T. Management of transfusion-dependent β-thalassemia (TDT): Expert insights and practical overview from the Middle East. Blood Rev. 2024, 63, 101138. [Google Scholar] [CrossRef]
  7. Evangelidis, P.; Evangelidis, N.; Vlachaki, E.; Gavriilaki, E. What is the role of complement in bystander hemolysis? Old concept, new insights. Expert. Rev. Hematol. 2024, 17, 107–116. [Google Scholar] [CrossRef]
  8. Shander, A.; Cappellini, M.D.; Goodnough, L.T. Iron overload and toxicity: The hidden risk of multiple blood transfusions. Vox Sang. 2009, 97, 185–197. [Google Scholar] [CrossRef]
  9. Pahuja, S.; Mandal, P. Alloimmunization and autoimmunization among multitransfused thalassemia and sickle cell disease patients. Pediatr. Hematol. Oncol. J. 2024, 9, 200–206. [Google Scholar] [CrossRef]
  10. Lal, A. Challenges in chronic transfusion for patients with thalassemia. Hematology 2020, 2020, 160–166. [Google Scholar] [CrossRef]
  11. Taher, A.T.; Musallam, K.M.; El-Beshlawy, A.; Karimi, M.; Daar, S.; Belhoul, K.; Saned, M.S.; Graziadei, G.; Cappellini, M.D. Age-related complications in treatment-naive patients with thalassaemia intermedia. Br. J. Haematol. 2010, 150, 486–489. [Google Scholar] [CrossRef]
  12. Taher, A.T.; Musallam, K.M.; Karimi, M.; El-Beshlawy, A.; Belhoul, K.; Daar, S.; Saned, M.S.; El-Chafic, A.H.; Fasulo, M.R.; Cappellini, M.D. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: The OPTIMAL CARE study. Blood 2010, 115, 1886–1892. [Google Scholar] [CrossRef]
  13. Haddad, A.; Tyan, P.; Radwan, A.; Mallat, N.; Taher, A. β-Thalassemia Intermedia: A Bird’s-Eye View. Turk. J. Haematol. 2014, 31, 5–16. [Google Scholar] [CrossRef] [PubMed]
  14. Ricchi, P.; Meloni, A.; Pistoia, L.; Spasiano, A.; Rita Gamberini, M.; Maggio, A.; Gerardi, C.; Messina, G.; Campisi, S.; Allo, M.; et al. Longitudinal follow-up of patients with thalassaemia intermedia who started transfusion therapy in adulthood: A cohort study. Br. J. Haematol. 2020, 191, 107–114. [Google Scholar] [CrossRef] [PubMed]
  15. Karimi, M.; Musallam, K.M.; Cappellini, M.D.; Daar, S.; El-Beshlawy, A.; Belhoul, K.; Saned, M.S.; Temraz, S.; Koussa, S.; Taher, A.T. Risk factors for pulmonary hypertension in patients with beta thalassemia intermedia. Eur. J. Intern. Med. 2011, 22, 607–610. [Google Scholar] [CrossRef] [PubMed]
  16. Taher, A.T.; Musallam, K.M.; Karimi, M.; El-Beshlawy, A.; Belhoul, K.; Daar, S.; Saned, M.; Cesaretti, C.; Cappellini, M.D. Splenectomy and thrombosis: The case of thalassemia intermedia. J. Thromb. Haemost. 2010, 8, 2152–2158. [Google Scholar] [CrossRef]
  17. Sleiman, J.; Tarhini, A.; Bou-Fakhredin, R.; Saliba, A.N.; Cappellini, M.D.; Taher, A.T. Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management. Int. J. Mol. Sci. 2018, 19, 182. [Google Scholar] [CrossRef]
  18. Musallam, K.M.; Cappellini, M.D.; Viprakasit, V.; Kattamis, A.; Rivella, S.; Taher, A.T. Revisiting the non-transfusion-dependent (NTDT) vs. transfusion-dependent (TDT) thalassemia classification 10 years later. Am. J. Hematol. 2021, 96, E54–E56. [Google Scholar] [CrossRef]
  19. Akiki, N.; Hodroj, M.H.; Bou-Fakhredin, R.; Matli, K.; Taher, A.T. Cardiovascular Complications in β-Thalassemia: Getting to the Heart of It. Thalass. Rep. 2023, 13, 38–50. [Google Scholar] [CrossRef]
  20. Meloni, A.; Pistoia, L.; Ricchi, P.; Maggio, A.; Cecinati, V.; Longo, F.; Sorrentino, F.; Borsellino, Z.; Salvo, A.; Rossi, V.; et al. Prognostic Role of Multiparametric Cardiac Magnetic Resonance in Neo Transfusion-Dependent Thalassemia. J. Clin. Med. 2024, 13, 1281. [Google Scholar] [CrossRef]
  21. Situ, Y.; Birch, S.C.M.; Moreyra, C.; Holloway, C.J. Cardiovascular magnetic resonance imaging for structural heart disease. Cardiovasc. Diagn. Ther. 2020, 10, 361–375. [Google Scholar] [CrossRef]
  22. Ipek, R.; Holland, J.; Cramer, M.; Rider, O. CMR to characterize myocardial structure and function in heart failure with preserved left ventricular ejection fraction. Eur. Heart J. Cardiovasc. Imaging 2024, 25, 1491–1504. [Google Scholar] [CrossRef]
  23. Simkowski, J.; Eck, B.; Wilson Tang, W.H.; Nguyen, C.; Kwon, D.H. Next-Generation Cardiac Magnetic Resonance Imaging Techniques for Characterization of Myocardial Disease. Curr. Treat. Options Cardiovasc. Med. 2024, 26, 243–254. [Google Scholar] [CrossRef] [PubMed]
  24. Grothues, F.; Moon, J.C.; Bellenger, N.G.; Smith, G.S.; Klein, H.U.; Pennell, D.J. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am. Heart J. 2004, 147, 218–223. [Google Scholar] [CrossRef] [PubMed]
  25. Messroghli, D.R.; Moon, J.C.; Ferreira, V.M.; Grosse-Wortmann, L.; He, T.; Kellman, P.; Mascherbauer, J.; Nezafat, R.; Salerno, M.; Schelbert, E.B.; et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J. Cardiovasc. Magn. Reson. 2017, 19, 75. [Google Scholar] [PubMed]
  26. Ferreira, V.M.; Piechnik, S.K. CMR Parametric Mapping as a Tool for Myocardial Tissue Characterization. Korean Circ. J. 2020, 50, 658–676. [Google Scholar] [CrossRef]
  27. Wood, J.C. Impact of iron assessment by MRI. Hematol. Am. Soc. Hematol. Educ. Program 2011, 2011, 443–450. [Google Scholar] [CrossRef]
  28. Pennell, D.J.; Udelson, J.E.; Arai, A.E.; Bozkurt, B.; Cohen, A.R.; Galanello, R.; Hoffman, T.M.; Kiernan, M.S.; Lerakis, S.; Piga, A.; et al. Cardiovascular function and treatment in beta-thalassemia major: A consensus statement from the American Heart Association. Circulation 2013, 128, 281–308. [Google Scholar] [CrossRef]
  29. Origa, R.; Barella, S.; Argiolas, G.M.; Bina, P.; Agus, A.; Galanello, R. No evidence of cardiac iron in 20 never- or minimally-transfused patients with thalassemia intermedia. Haematologica 2008, 93, 1095–1096. [Google Scholar] [CrossRef]
  30. Roghi, A.; Cappellini, M.D.; Wood, J.C.; Musallam, K.M.; Patrizia, P.; Fasulo, M.R.; Cesaretti, C.; Taher, A.T. Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: An MRI T2* study. Ann. Hematol. 2010, 89, 585–589. [Google Scholar] [CrossRef]
  31. Liguori, C.; Pitocco, F.; Di Giampietro, I.; De Vivo, A.E.; Schena, E.; Giurazza, F.; Sorrentino, F.; Zobel, B.B. Magnetic resonance comparison of left-right heart volumetric and functional parameters in thalassemia major and thalassemia intermedia patients. Biomed. Res. Int. 2015, 2015, 857642. [Google Scholar] [CrossRef]
  32. Taher, A.T.; Musallam, K.M.; Wood, J.C.; Cappellini, M.D. Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. Am. J. Hematol. 2010, 85, 288–290. [Google Scholar] [CrossRef]
  33. Meloni, A.; Pistoia, L.; Gamberini, M.R.; Ricchi, P.; Cecinati, V.; Sorrentino, F.; Cuccia, L.; Allo, M.; Righi, R.; Fina, P.; et al. The Link of Pancreatic Iron with Glucose Metabolism and Cardiac Iron in Thalassemia Intermedia: A Large, Multicenter Observational Study. J. Clin. Med. 2021, 10, 5561. [Google Scholar] [CrossRef] [PubMed]
  34. Ricchi, P.; Meloni, A.; Pistoia, L.; Spasiano, A.; Spiga, A.; Allo, M.; Gamberini, M.R.; Lisi, R.; Campisi, S.; Peluso, A.; et al. The effect of desferrioxamine chelation versus no therapy in patients with non transfusion-dependent thalassaemia: A multicenter prospective comparison from the MIOT network. Ann. Hematol. 2018, 97, 1925–1932. [Google Scholar] [CrossRef] [PubMed]
  35. Ricchi, P.; Meloni, A.; Spasiano, A.; Neri, M.G.; Gamberini, M.R.; Cuccia, L.; Caruso, V.; Gerardi, C.; D’Ascola, D.G.; Rosso, R.; et al. Extramedullary hematopoiesis is associated with lower cardiac iron loading in chronically transfused thalassemia patients. Am. J. Hematol. 2015, 90, 1008–1012. [Google Scholar] [CrossRef] [PubMed]
  36. Garbowski, M.W.; Evans, P.; Vlachodimitropoulou, E.; Hider, R.; Porter, J.B. Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin. Haematologica 2017, 102, 1640–1649. [Google Scholar] [CrossRef]
  37. Meloni, A.; Pistoia, L.; Ricchi, P.; Longo, F.; Cecinati, V.; Sorrentino, F.; Cuccia, L.; Corigliano, E.; Rossi, V.; Righi, R.; et al. Multiparametric cardiac magnetic resonance in patients with thalassemia intermedia: New insights from the E-MIOT network. Radiol. Med. 2024, 129, 879–889. [Google Scholar] [CrossRef]
  38. Varat, M.A.; Adolph, R.J.; Fowler, N.O. Cardiovascular effects of anemia. Am. Heart J. 1972, 83, 415–426. [Google Scholar] [CrossRef]
  39. Dahiya, A.; Vollbon, W.; Jellis, C.; Prior, D.; Wahi, S.; Marwick, T. Echocardiographic assessment of raised pulmonary vascular resistance: Application to diagnosis and follow-up of pulmonary hypertension. Heart 2010, 96, 2005–2009. [Google Scholar] [CrossRef]
  40. Lindsay, J., Jr.; Meshel, J.C.; Patterson, R.H. The cardiovascular manifestations of sickle cell disease. Arch. Intern. Med. 1974, 133, 643–651. [Google Scholar] [CrossRef]
  41. Kremastinos, D.T.; Tsiapras, D.P.; Tsetsos, G.A.; Rentoukas, E.I.; Vretou, H.P.; Toutouzas, P.K. Left ventricular diastolic Doppler characteristics in beta-thalassemia major. Circulation 1993, 88, 1127–1135. [Google Scholar] [CrossRef]
  42. Ramazzotti, A.; Pepe, A.; Positano, V.; Rossi, G.; De Marchi, D.; Brizi, M.G.; Luciani, A.; Midiri, M.; Sallustio, G.; Valeri, G.; et al. Multicenter validation of the magnetic resonance t2* technique for segmental and global quantification of myocardial iron. J. Magn. Reson. Imaging 2009, 30, 62–68. [Google Scholar] [CrossRef]
  43. Meloni, A.; Luciani, A.; Positano, V.; De Marchi, D.; Valeri, G.; Restaino, G.; Cracolici, E.; Caruso, V.; Dell’amico, M.C.; Favilli, B.; et al. Single region of interest versus multislice T2* MRI approach for the quantification of hepatic iron overload. J. Magn. Reson. Imaging 2011, 33, 348–355. [Google Scholar] [CrossRef] [PubMed]
  44. Meloni, A.; Restaino, G.; Borsellino, Z.; Caruso, V.; Spasiano, A.; Zuccarelli, A.; Valeri, G.; Toia, P.; Salvatori, C.; Positano, V.; et al. Different patterns of myocardial iron distribution by whole-heart T2* magnetic resonance as risk markers for heart complications in thalassemia major. Int. J. Cardiol. 2014, 177, 1012–1019. [Google Scholar] [CrossRef] [PubMed]
  45. Wood, J.C.; Enriquez, C.; Ghugre, N.; Tyzka, J.M.; Carson, S.; Nelson, M.D.; Coates, T.D. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005, 106, 1460–1465. [Google Scholar] [CrossRef] [PubMed]
  46. Cerqueira, M.D.; Weissman, N.J.; Dilsizian, V.; Jacobs, A.K.; Kaul, S.; Laskey, W.K.; Pennell, D.J.; Rumberger, J.A.; Ryan, T.; Verani, M.S. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002, 105, 539–542. [Google Scholar]
  47. Positano, V.; Pepe, A.; Santarelli, M.F.; Scattini, B.; De Marchi, D.; Ramazzotti, A.; Forni, G.; Borgna-Pignatti, C.; Lai, M.E.; Midiri, M.; et al. Standardized T2* map of normal human heart in vivo to correct T2* segmental artefacts. NMR Biomed. 2007, 20, 578–590. [Google Scholar] [CrossRef]
  48. Angelucci, E.; Brittenham, G.M.; McLaren, C.E.; Ripalti, M.; Baronciani, D.; Giardini, C.; Galimberti, M.; Polchi, P.; Lucarelli, G. Hepatic iron concentration and total body iron stores in thalassemia major. N. Engl. J. Med. 2000, 343, 327–331. [Google Scholar] [CrossRef]
  49. Anderson, L.J.; Holden, S.; Davis, B.; Prescott, E.; Charrier, C.C.; Bunce, N.H.; Firmin, D.N.; Wonke, B.; Porter, J.; Walker, J.M.; et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur. Heart J. 2001, 22, 2171–2179. [Google Scholar] [CrossRef]
  50. Alfakih, K.; Plein, S.; Thiele, H.; Jones, T.; Ridgway, J.P.; Sivananthan, M.U. Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady-state free precession imaging sequences. J. Magn. Reson. Imaging 2003, 17, 323–329. [Google Scholar] [CrossRef]
  51. Meloni, A.; Righi, R.; Missere, M.; Renne, S.; Schicchi, N.; Gamberini, M.R.; Cuccia, L.; Lisi, R.; Spasiano, A.; Roberti, M.G.; et al. Biventricular Reference Values by Body Surface Area, Age, and Gender in a Large Cohort of Well-Treated Thalassemia Major Patients Without Heart Damage Using a Multiparametric CMR Approach. J. Magn. Reson. Imaging 2021, 53, 61–70. [Google Scholar] [CrossRef]
  52. Aquaro, G.D.; Camastra, G.; Monti, L.; Lombardi, M.; Pepe, A.; Castelletti, S.; Maestrini, V.; Todiere, G.; Masci, P.; di Giovine, G.; et al. Reference values of cardiac volumes, dimensions, and new functional parameters by MR: A multicenter, multivendor study. J. Magn. Reson. Imaging 2016, 45, 1055–1067. [Google Scholar] [CrossRef]
  53. Wang, Y.; Moss, J.; Thisted, R. Predictors of body surface area. J. Clin. Anesth. 1992, 4, 4–10. [Google Scholar] [CrossRef] [PubMed]
  54. Jenista, E.R.; Wendell, D.C.; Azevedo, C.F.; Klem, I.; Judd, R.M.; Kim, R.J.; Kim, H.W. Revisiting how we perform late gadolinium enhancement CMR: Insights gleaned over 25 years of clinical practice. J. Cardiovasc. Magn. Reson. 2023, 25, 18. [Google Scholar] [CrossRef] [PubMed]
  55. Pennell, D.; Porter, J.B.; Cappellini, M.D.; Li, C.-K.; Aydinok, Y.; Lee, C.L.; Kattamis, A.; Smith, G.; Habr, D.; Domokos, G.; et al. Efficacy and Safety of Deferasirox (Exjade®) in Reducing Cardiac Iron in Patients with β-Thalassemia Major: Results from the Cardiac Substudy of the EPIC Trial. Blood 2008, 112, 3873. [Google Scholar] [CrossRef]
  56. Wood, J.C.; Thompson, A.A.; Paley, C.; Kang, B.; Giardina, P.; Harmatz, P.; Virkus, J.; Coates, T.D. Deferasirox (Exjade®) Monotherapy Significantly Reduces Cardiac Iron Burden in Chronically Transfused β-Thalassemia Patients: An MRI T2* Study. Blood 2008, 112, 3882. [Google Scholar] [CrossRef]
  57. Berdoukas, V.; Farmaki, K.; Carson, S.; Wood, J.; Coates, T. Treating thalassemia major-related iron overload: The role of deferiprone. J. Blood Med. 2012, 3, 119–129. [Google Scholar] [CrossRef]
  58. Pepe, A.; Meloni, A.; Pistoia, L.; Cuccia, L.; Gamberini, M.R.; Lisi, R.; D’Ascola, D.G.; Rosso, R.; Allo, M.; Spasiano, A.; et al. MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine. Br. J. Haematol. 2018, 183, 783–795. [Google Scholar] [CrossRef]
  59. Chuang, T.Y.; Li, J.P.; Weng, T.F.; Wu, K.H.; Chao, Y.H. Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. Ann. Hematol. 2020, 99, 2289–2294. [Google Scholar] [CrossRef]
  60. Cui, X.; Jing, M.; Ren, L.; Hou, X.; Song, Q.; Li, K.; Wang, X. Evaluation of left ventricular systolic function in patients with iron deficiency anemia based on non-invasive left ventricular pressure–strain loops. Biomed. Eng. OnLine 2024, 23, 82. [Google Scholar] [CrossRef]
  61. Pfeffer, M.A.; Braunwald, E.; Moye, L.A.; Basta, L.; Brown, E.J., Jr.; Cuddy, T.E.; Davis, B.R.; Geltman, E.M.; Goldman, S.; Flaker, G.C.; et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. 1992, 327, 669–677. [Google Scholar] [CrossRef]
  62. Cygankiewicz, I.; Zareba, W.; Vazquez, R.; Bayes-Genis, A.; Pascual, D.; Macaya, C.; Almendral, J.; Fiol, M.; Bardaji, A.; Gonzalez-Juanatey, J.R.; et al. Risk stratification of mortality in patients with heart failure and left ventricular ejection fraction >35%. Am. J. Cardiol. 2009, 103, 1003–1010. [Google Scholar] [CrossRef]
  63. Tops, L.F.; Delgado, V.; Marsan, N.A.; Bax, J.J. Myocardial strain to detect subtle left ventricular systolic dysfunction. Eur. J. Heart Fail. 2017, 19, 307–313. [Google Scholar] [CrossRef] [PubMed]
  64. Chung, F.P.; Chao, T.F.; Lee, A.S.; Sung, K.T.; Huang, W.H.; Hsiao, C.C.; Su, C.H.; Yang, L.T.; Chen, Y.J.; Chen, Y.Y.; et al. Discriminative Ability of Left Ventricular Strain in Mildly Reduced Ejection Fraction Heart Failure. JACC Adv. 2023, 2, 100654. [Google Scholar] [CrossRef] [PubMed]
  65. Bashir, Z.; Ataklte, F.; Wang, S.; Chen, E.W.; Kadiyala, V.; Sherrod, C.F.; Has, P.; Song, C.; Ventetuolo, C.E.; Simmons, J.; et al. Comparison of Left Ventricular Global Longitudinal Strain and Left Ventricular Ejection Fraction in Acute Respiratory Failure Patients Requiring Invasive Mechanical Ventilation. J. Cardiovasc. Dev. Dis. 2024, 11, 339. [Google Scholar] [CrossRef] [PubMed]
  66. Meloni, A.; Saba, L.; Positano, V.; Pistoia, L.; Campanella, A.; Spasiano, A.; Putti, M.C.; Fotzi, I.; Cossu, A.; Corigliano, E.; et al. Global longitudinal strain by cardiac magnetic resonance is associated with cardiac iron and complications in beta-thalassemia major patients. Int. J. Cardiol. 2024, 413, 132319. [Google Scholar] [CrossRef]
  67. Detterich, J.; Noetzli, L.; Dorey, F.; Bar-Cohen, Y.; Harmatz, P.; Coates, T.; Wood, J. Electrocardiographic consequences of cardiac iron overload in thalassemia major. Am. J. Hematol. 2012, 87, 139–144. [Google Scholar] [CrossRef]
  68. Kraigher-Krainer, E.; Shah, A.M.; Gupta, D.K.; Santos, A.; Claggett, B.; Pieske, B.; Zile, M.R.; Voors, A.A.; Lefkowitz, M.P.; Packer, M.; et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J. Am. Coll. Cardiol. 2014, 63, 447–456. [Google Scholar] [CrossRef]
Table 1. Comparison of baseline demographic, clinical, and MRI data.
Table 1. Comparison of baseline demographic, clinical, and MRI data.
NTDT Patients
(N = 32)		Neo-TDT Patients
(N = 58)		p-Value
Age (years)42.78 ± 12.6244.08 ± 14.130.666
Female gender, N (%)17 (53.1)27 (46.6)0.550
Splenectomy, N (%)19 (59.4)49 (84.5)0.008
On chelation therapy, N (%)13 (40.6)57 (98.3)<0.0001
Serum hemoglobin (g/dL)8.99 ± 0.929.62 ± 0.620.003
Mean serum ferritin (ng/mL)575.21 ± 631.42753.95 ± 688.940.077
MRI LIC (mg/g dL)7.23 ± 7.424.86 ± 7.560.002
Hepatic iron overload, N (%)24 (75.0)21 (36.2)<0.0001
Global heart T2* (ms)40.27 ± 6.4539.13 ± 4.580.246
Global heart T2* < 20 ms, N (%)1 (3.1)0 (0.0)0.356
Al least one cardiac segment with T2* < 20 ms, N (%)3 (9.4)4 (6.9)0.696
LV end-diastolic volume index (mL/m2)94.19 ± 17.1486.34 ± 16.220.034
LV end-systolic volume index (mL/m2)35.28 ± 11.0831.30 ± 11.720.078
LV stroke volume index (mL/m2)58.63 ± 9.4955.46 ± 10.080.148
LV mass index (g/m2)62.03 ± 12.6158.02 ± 11.720.134
LV cardiac index (L/min/m2)4.08 ± 0.873.67 ± 0.890.040
LV ejection fraction (%)63.00 ± 5.7465.29 ± 7.310.129
RV end-diastolic volume index (mL/m2)88.92 ± 19.1982.53 ± 16.660.103
RV end-systolic volume index (mL/m2)35.29 ± 14.6929.16 ± 9.580.059
RV stroke volume index (mL/m2)55.48 ±11.2253.13 ± 10.740.331
RV ejection fraction (%)62.50 ± 5.8564.21 ± 6.460.218
Left atrial area index (cm2/m2)13.74 ± 2.5913.12 ± 2.480.526
Right atrial area index (cm2/m2)12.54 ± 2.4412.08 ± 1.950.420
Replacement myocardial fibrosis, N (%)4/16 (25.0)4/19 (21.1)0.782
LIC = liver iron concentration, LV = left ventricular, MRI = magnetic resonance imaging, N = number, NTDT = non-transfusion dependent thalassemia, RV = right ventricular, TDT = transfusion dependent thalassemia.
Table 2. Changes of MRI parameters between baseline and follow-up MRI scans in NTDT patients.
Table 2. Changes of MRI parameters between baseline and follow-up MRI scans in NTDT patients.
Baseline MRIFollow-Up MRIp-Value
MRI LIC (mg/g dw)7.23 ± 7.426.25 ± 4.630.128
Global heart T2* (ms)40.27 ± 6.4541.84 ± 5.160.331
LV end-diastolic volume index (mL/m2)94.19 ± 17.1496.69 ± 16.610.204
LV end-systolic volume index (mL/m2)35.28 ± 11.0835.81 ± 10.390.722
LV stroke volume index (mL/m2)58.63 ± 9.4961.35 ± 9.850.139
LV mass index (g/m2)62.03 ± 12.6164.04 ± 10.940.469
LV cardiac index (L/min/m2)4.08 ± 0.874.32 ± 0.870.107
LV ejection fraction (%)63.00 ± 5.7464.00 ± 4.980.408
RV end-diastolic volume index (mL/m2)88.92 ± 19.1993.75 ± 19.290.063
RV end-systolic volume index (mL/m2)35.29 ± 14.6935.97 ± 10.830.155
RV stroke volume index (mL/m2)55.48 ± 11.2258.18 ± 10.350.187
RV ejection fraction (%)62.50 ± 5.8562.34 ± 5.210.874
Left atrial area index (cm2/m2)13.74 ± 2.5913.97 ± 3.680.738
Right atrial area index (cm2/m2)12.54 ± 2.4412.78 ± 2.970.454
LIC = liver iron concentration, LV = left ventricular, MRI = magnetic resonance imaging, RV = right ventricular.
Table 3. Association of baseline serum hemoglobin levels with changes between baseline and follow-up MRI scans in biventricular function parameters and bi-atrial areas.
Table 3. Association of baseline serum hemoglobin levels with changes between baseline and follow-up MRI scans in biventricular function parameters and bi-atrial areas.
NTDT Patients
(N = 32)		Neo-TDT Patients
(N = 58)
Correlation (r, p-Value) with Baseline Serum Hemoglobin Levels
Diff LV end-diastolic volume indexr = −0.003, p = 0.989r = −0.169, p = 0.231
Diff LV end-systolic volume indexr = −0.282, p = 0.154r = 0.030, p = 0.834
Diff LV stroke volume indexr = 0.350, p = 0.073r = −0.280, p = 0.084
Diff LV mass indexr = −0.330, p = 0.092r = 0.004, p = 0.978
Diff LV cardiac indexr = 0.225, p = 0.260r = −0.086, p = 0.545
Diff LV ejection fractionr = 0.179, p = 0.074r = −0.045, p = 0.574
Diff RV end-diastolic volume indexr = −0.271, p = 0.171r = 0.062, p = 0.661
Diff RV end-systolic volume indexr = 0.140, p = 0.485r = −0.077, p = 0.586
Diff RV stroke volume indexr = 0.163, p = 0416r = −0.216, p = 0.125
Diff RV ejection fractionr = 0.310, p = 0.116r = −0.084, p = 0.556
Diff left atrial area index r = −0.182, p = 0.430r = −0.110, p = 0.523
Diff right atrial area indexr = 0.148, p = 0.522r = −0.283, p = 0.094
Diff = difference, LV = left ventricular, N = number, NTDT = non-transfusion dependent thalassemia, RV = right ventricular, TDT = transfusion dependent thalassemia.
Table 4. Changes of MRI parameters between baseline and follow-up MRI scans in neo-TDT patients.
Table 4. Changes of MRI parameters between baseline and follow-up MRI scans in neo-TDT patients.
Baseline MRIFollow-Up MRIp-Value
MRI LIC (mg/g dw)4.86 ± 7.564.45 ± 6.530.792
Global heart T2* (ms)39.13 ± 4.5839.21 ± 5.530.941
LV end-diastolic volume index (mL/m2)86.34 ± 16.2284.24 ± 16.650.195
LV end-systolic volume index (mL/m2)31.30 ± 11.7230.83 ± 9.850.721
LV stroke volume index (mL/m2)55.46 ± 10.0854.21 ± 13.510.036
LV mass index (g/m2)58.02 ± 11.7258.78 ± 10.630.528
LV cardiac index (L/min/m2)3.67 ± 0.893.45 ± 0.970.031
LV ejection fraction (%)65.29 ± 7.3163.95 ± 7.150.098
RV end-diastolic volume index (mL/m2)82.53 ± 16.6678.63 ± 18.490.034
RV end-systolic volume index (mL/m2)29.16 ± 9.5729.31 ± 8.650.929
RV stroke volume index (mL/m2)53.13 ± 10.7450.14 ± 11.490.033
RV ejection fraction (%)64.21 ± 6.4662.91 ± 6.170.099
Left atrial area index (cm2/m2)13.12 ± 2.4813.54 ± 2.490.188
Right atrial area index (cm2/m2)12.08 ± 1.9512.14 ± 2.020.844
LIC = liver iron concentration, LV = left ventricular, MRI = magnetic resonance imaging, RV = right ventricular.
Table 5. Comparison of mean changes from baseline in MRI parameters between NTDT and neo-TDT patients.
Table 5. Comparison of mean changes from baseline in MRI parameters between NTDT and neo-TDT patients.
NTDT Patients
(N = 32)		Neo-TDT Patients
(N = 58)		p-Value
Mean Diff MRI LIC (mg/g dw)−0.97 ± 5.09−0.41 ± 3.640.433
Mean Diff Global heart T2* (ms)1.58 ± 5.700.08 ± 4.300.316
Mean Diff LV end-diastolic volume index (mL/m2)2.50 ± 10.89−2.10 ± 12.220.079
Mean Diff LV end-systolic volume index (mL/m2)0.53 ± 8.33−0.47 ± 10.010.856
Mean Diff LV stroke volume index (mL/m2)2.72 ± 10.13−1.25 ± 10.990.006
Mean Diff LV mass index (g/m2)2.01 ± 12.450.76 ± 9.110.627
Mean Diff LV cardiac index (l/min/m2)0.24 ± 0.83−0.22 ± 0.760.009
Mean Diff LV ejection fraction (%)1.00 ± 6.74−1.34 ± 5.710.102
Mean Diff RV end-diastolic volume index (mL/m2)4.83 ± 4.18−3.91 ± 13.670.005
Mean Diff RV end-systolic volume index (mL/m2)0.68 ± 9.910.14 ± 5.570.742
Mean Diff RV stroke volume index (mL/m2)2.70 ± 11.32−2.99 ± 10.430.018
Mean Diff RV ejection fraction (%)−0.16 ± 5.51−1.29 ± 5.870.403
Mean Diff left atrial area index (cm2/m2)0.23 ± 3.220.42 ± 2.030.554
Mean Diff right atrial area index (cm2/m2)0.25 ± 1.530.06 ± 2.090.484
Diff = difference, LIC = liver iron concentration, LV = left ventricular, MRI = magnetic resonance imaging, N = number, NTDT = non-transfusion dependent thalassemia, RV = right ventricular, TDT = transfusion dependent thalassemia.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Meloni, A.; Pistoia, L.; Longo, F.; Spasiano, A.; Cecinati, V.; Corigliano, E.; Borsellino, Z.; Fotzi, I.; Positano, V.; Zerbini, M.; et al. Prospective Assessment of Cardiac Iron Deposition, Morphology, and Function by Magnetic Resonance Imaging in Non-Transfusion-Dependent and Neo-Transfusion-Dependent Thalassemia. J. Clin. Med. 2025, 14, 4020. https://doi.org/10.3390/jcm14124020

AMA Style

Meloni A, Pistoia L, Longo F, Spasiano A, Cecinati V, Corigliano E, Borsellino Z, Fotzi I, Positano V, Zerbini M, et al. Prospective Assessment of Cardiac Iron Deposition, Morphology, and Function by Magnetic Resonance Imaging in Non-Transfusion-Dependent and Neo-Transfusion-Dependent Thalassemia. Journal of Clinical Medicine. 2025; 14(12):4020. https://doi.org/10.3390/jcm14124020

Chicago/Turabian Style

Meloni, Antonella, Laura Pistoia, Filomena Longo, Anna Spasiano, Valerio Cecinati, Elisabetta Corigliano, Zelia Borsellino, Ilaria Fotzi, Vincenzo Positano, Michela Zerbini, and et al. 2025. "Prospective Assessment of Cardiac Iron Deposition, Morphology, and Function by Magnetic Resonance Imaging in Non-Transfusion-Dependent and Neo-Transfusion-Dependent Thalassemia" Journal of Clinical Medicine 14, no. 12: 4020. https://doi.org/10.3390/jcm14124020

APA Style

Meloni, A., Pistoia, L., Longo, F., Spasiano, A., Cecinati, V., Corigliano, E., Borsellino, Z., Fotzi, I., Positano, V., Zerbini, M., Renne, S., Barbuto, L., Clemente, A., & Ricchi, P. (2025). Prospective Assessment of Cardiac Iron Deposition, Morphology, and Function by Magnetic Resonance Imaging in Non-Transfusion-Dependent and Neo-Transfusion-Dependent Thalassemia. Journal of Clinical Medicine, 14(12), 4020. https://doi.org/10.3390/jcm14124020

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop